Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?
Covered in this story
What has happened since
- Crispr Therapeutics AG is up 10.2% since this was published, 71 days ago.
- Morgan Stanley is down 9.5% since this was published, 71 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Morgan Stanley’s $60 target on $CRSP is on the record and being tracked to Jul 2027 (12-month default), scored on the close that day.
Morgan Stanley’s track record →Call it yourself
No member calls on $CRSP yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Crispr Therapeutics AG →Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.